Comparative Pharmacology
Head-to-head clinical analysis: INDICLOR versus MELOXICAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDICLOR versus MELOXICAM.
INDICLOR vs MELOXICAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription.
Selective inhibitor of cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and inflammation.
INDICLOR is not a recognized drug; no standard dosing available.
7.5-15 mg orally once daily; maximum 15 mg/day. For osteoarthritis, rheumatoid arthritis: 7.5 mg once daily, may increase to 15 mg/day if needed. For juvenile rheumatoid arthritis, weight-based dosing.
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 10-15 hours) in patients with normal renal function; prolonged in renal impairment (up to 25 hours in severe cases).
Clinical Note
moderateMeloxicam + Gatifloxacin
"Meloxicam may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateMeloxicam + Rosoxacin
"Meloxicam may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateMeloxicam + Levofloxacin
"Meloxicam may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateMeloxicam + Trovafloxacin
"Meloxicam may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life: 15–20 hours. Clinical context: Allows once-daily dosing; steady-state achieved in 3–5 days.
Primarily renal excretion (approximately 70% unchanged drug); biliary/fecal excretion accounts for about 10-15% as metabolites.
Approximately 50% renal excretion of unchanged drug and metabolites; 50% fecal excretion via bile. Renal elimination accounts for ~5% unchanged meloxicam; the remainder as metabolites (primarily oxidative and glucuronide conjugates).
Category C
Category D/X
NSAID
NSAID